PDE5A Polymorphisms Influence on Sildenafil Treatment Success

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Endocrinology

Background:

• Erectile dysfunction (ED) is frequently associated with diabetes and cardiovascular disease.
• Selective phosphodiesterase type 5 inhibitors are a primary treatment for ED.
• Patient response variability to PDE5 inhibitors suggests underlying genetic or metabolic factors.

Purpose of the Study:

• To investigate the association between PDE5A gene polymorphisms, diabetes, and sildenafil treatment efficacy in ED patients.
• To determine if specific PDE5A gene variants influence treatment outcomes in relation to glycemic status.

Main Methods:

• A prospective cohort study of 170 Caucasian males with ED and ischemic heart disease.
• Evaluation of ED using the International Index for Erectile Function (IIEF-5) before and after sildenafil 50 mg treatment.
• Genotyping for PDE5A polymorphisms (rs12646525, rs3806808) and measurement of glycemic markers (glucose, HbA1c).

Main Results:

• The G-allele of the rs3806808 polymorphism was associated with a poorer response to sildenafil compared to TT-homozygotes, especially in non-diabetic individuals.
• No significant differences in treatment response were observed for the rs12646525 polymorphism.
• Logistic regression indicated that non-diabetic carriers of major alleles for both polymorphisms had a higher likelihood of responding to treatment than diabetic patients with minor alleles.

Conclusions:

• Sildenafil treatment response for ED is influenced by PDE5A gene polymorphisms and a patient's glycemic status.
• Genetic factors and diabetes management are crucial considerations for optimizing ED treatment outcomes.